Objective To compare the short-term therapeutic effect, adverse reaction and influence on immune function between chrono-chemotherapy and routine-chemotherapy with docetaxel +cisplatin(DP)combined with concurrent chemoradiotherapy with cisplatin(DDP)in locally advanced(Ⅲ,Ⅳa stage)nasopharyngeal carcinoma(NPC).Methods 70 cases of newly diagnosed locally advanced NPC were randomly divided into group A and group B,35 cases in each group.Two groups of patients were treated with two cycles of neoadjuvant chemotherapy with DP combined with concurrent chemoradiotherapy with DDP.Both nereoadjuvant chemotherapy and concurrent chemotherapy of patients in group A were administrated with chrono-chemotherapy.Both nereoadjuvant chemotherapy and concurrent chemotherapy of patients in group B were administrated with routine-chemotherapy.Therapeutic effect,adverse reactions and other indicators were observed in both groups.Results After 3 months,there was no sifnificant difference of short term total efficacy between two groups in nasopharyngeal primary tumor(35 cases vs.34 cases),cervical lymph node(32 cases vs.31 cases).The incidence of adverse reactions of marrow toxicity(WBC,Hb,PLT)in group A was lower than group B(P<0.05),the incidence of digestive tract(nausea and vomiting,diarrhea)in group A was lower than group B(P<0.05),while there was no significant difference in oral mucositis between two groups(P<0.05).The high creatinine incidence in group A was lower than group B(P<0.05).There was no significant difference in high blood urea nitrogen and high transaminase incidences between two groups.After treatment, the T lymphocytes ( CD3 +, CD4 +, CD8 +, CD4 +/CD8 +) had no change in group A,the T lymphocytes(CD3 +,CD4 +)in group B decreased significantly compared with pre-treatment(P<0.05),and were lower than group A(P<0.05).Conclusion Adverse reactions and the degree of decline in cellular immune function of chrono-chemotherapy are lower than routine-chemotherapy in locally advanced NPC.

Objective:To explore the relationship between drug evidence and core prescription for depression.Methods:We retrieved literature of TCM for depression from CNKI, VIP and Wangfang databases to November 2019, 30th as well as there cords from Ancient and Modern Medical Records Cloud Platform (V 1.5). The Excel 2010 was used to establish the standardized database of medical records. After the standardization of medicines, Ancient and Modern Medical Records Cloud Platform (V1.5) statistics methodswere used for association rules analysis, complex networks, and analysis of drugs’ frequency, medical characteristics, core prescription drugs.Results:A total of 632 effective prescriptions were included, involving a total of 527 drugs. The results of frequency of herbs showed that 23 kinds of high-frequency herbs were obtained. Bupleuri Radix was the most frequently used medicine. Most herbs are warm or flat, with pungent, sweet and bitter in taste, belonging to the lung, liver, heart and spleen meridians. A total of 25 drug-pair association and 13 TCM association were obtained by association rule analysis. Conclusions:TCM treatment for depression is mainly based on soothing the liver and regulating qi, clearing the heart and calming the nerves. Bupleuri Radix, Curcumae Radix, Paeoniae Radix Alba, Chuanxiong Rhizoma, Ziziphi Spinosae Semen are the basic prescriptions. Angelicae Sinensis Radix, Ophiopogonis Radix, Albiziae Cortex, Polygalae Radix, Poria are used as reference.

Objective To compare the effects of intravenous thrombolysis with tenecteplase com-bined with endovascular treatment versus alteplase combined with endovascular treatment in patients with acute ischemic stroke(AIS).Methods A total of 98 patients with AIS in the hospital from Jan-uary 2021 to October 2022 were randomly divided into alteplase group and tenecteplase group,with 49 cases in each group.The alteplase group received alteplase thrombolysis combined with endovascular treatment,while the tenecteplase group received tenecteplase combined with endovascular treatment.General clinical materials were compared between the two groups;the National Institutes of Health Stroke Scale(NIHSS)scores at baseline(T0),1 hour after thrombolysis(T1),24 hours after endo-vascular treatment(T2),7 days after endovascular treatment(T3),and at discharge(T4)were com-pared between two groups;the modified Rankin Scale(mRS)scores and Barthel index(BI)scores at T0,30 days after endovascular treatment(T5),and 90 days after endovascular treatment(T6)were also compared between two groups;the length of hospital stay,occurrence of complications,and clini-cal efficacy were compared between the two groups.Results There were no significant differences in age,gender distribution,body mass index(BMI),hypertension,diabetes,coronary heart disease,smoking,alcoholism,cerebral infarction volume,infarction location,and clinical classification be-tween the two groups(P＞0.05).Compared with the alteplase group,the NIHSS scores at T,,T2,T3 and T4 were significantly lower in the tenecteplase group(P＜0.05).Similarly,the mRS scores at T5 and T6 were significantly lower while the BI scores at T5 and T6 were significantly higher in the tenecteplase group than the alteplase group(P＜0.05).The length of hospital stay was significantly shorter in the tenecteplase group than the alteplase group(P＜0.05).The incidence rates of post-treatment complications such as cerebral hemorrhage,gastrointestinal bleeding,skin and oral muco-sa bleeding,atrial fibrillation,and hypotension in the alteplase group were 10.20％,2.04％,8.16％,0％,and 8.16％respectively,while those in the tenecteplase group were 2.04％,4.08％,6.12％,2.04％,and 4.08％respectively;the incidence rate of cerebral hemorrhage in the tenecteplase group was significantly lower than the alteplase group(P＜0.05).The total effec-tive rate was 85.71％in the alteplase group,which was significantly lower than the 91.84％in the tenecteplase group(P＜0.05).Conclusion Compared with alteplase bridging therapy,tenecte-plase bridging therapy shows better clinical outcomes,which can improve the quality of life and prognosis of patients with AIS to a certain extent,reduce the probability of cerebral hemorrhage,and enhance clinical efficacy.

Objective To compare the effects of intravenous thrombolysis with tenecteplase com-bined with endovascular treatment versus alteplase combined with endovascular treatment in patients with acute ischemic stroke(AIS).Methods A total of 98 patients with AIS in the hospital from Jan-uary 2021 to October 2022 were randomly divided into alteplase group and tenecteplase group,with 49 cases in each group.The alteplase group received alteplase thrombolysis combined with endovascular treatment,while the tenecteplase group received tenecteplase combined with endovascular treatment.General clinical materials were compared between the two groups;the National Institutes of Health Stroke Scale(NIHSS)scores at baseline(T0),1 hour after thrombolysis(T1),24 hours after endo-vascular treatment(T2),7 days after endovascular treatment(T3),and at discharge(T4)were com-pared between two groups;the modified Rankin Scale(mRS)scores and Barthel index(BI)scores at T0,30 days after endovascular treatment(T5),and 90 days after endovascular treatment(T6)were also compared between two groups;the length of hospital stay,occurrence of complications,and clini-cal efficacy were compared between the two groups.Results There were no significant differences in age,gender distribution,body mass index(BMI),hypertension,diabetes,coronary heart disease,smoking,alcoholism,cerebral infarction volume,infarction location,and clinical classification be-tween the two groups(P＞0.05).Compared with the alteplase group,the NIHSS scores at T,,T2,T3 and T4 were significantly lower in the tenecteplase group(P＜0.05).Similarly,the mRS scores at T5 and T6 were significantly lower while the BI scores at T5 and T6 were significantly higher in the tenecteplase group than the alteplase group(P＜0.05).The length of hospital stay was significantly shorter in the tenecteplase group than the alteplase group(P＜0.05).The incidence rates of post-treatment complications such as cerebral hemorrhage,gastrointestinal bleeding,skin and oral muco-sa bleeding,atrial fibrillation,and hypotension in the alteplase group were 10.20％,2.04％,8.16％,0％,and 8.16％respectively,while those in the tenecteplase group were 2.04％,4.08％,6.12％,2.04％,and 4.08％respectively;the incidence rate of cerebral hemorrhage in the tenecteplase group was significantly lower than the alteplase group(P＜0.05).The total effec-tive rate was 85.71％in the alteplase group,which was significantly lower than the 91.84％in the tenecteplase group(P＜0.05).Conclusion Compared with alteplase bridging therapy,tenecte-plase bridging therapy shows better clinical outcomes,which can improve the quality of life and prognosis of patients with AIS to a certain extent,reduce the probability of cerebral hemorrhage,and enhance clinical efficacy.